In real-world studies, this first-in-class test outperformed leading antibody tests.
Knowledge of prior COVID-19 infection is critically important for those who believe they may have been infected with the virus but have not been able to confirm a diagnosis. T-Detect is currently under review by the
'The impact of COVID-19 has become its own public health crisis, with millions of people, like me, who are dealing with serious, long-term effects of this virus,' said
Patients can order T-Detect COVID online at www.t-detect.com by answering a few eligibility questions through a secure portal. A virtual provider will authorize a prescription and patients can have their blood drawn by a mobile phlebotomist at their home or they can visit one of nearly 2,000
'T-Detect COVID is the first T-cell test for patients and the first product resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft,' said
Until now, antibody tests have been the primary way to determine recent or prior COVID-19 infection. T-cell tests take an entirely new approach to determine prior infection by looking at a different but equally important part of our immune system, the T cell. In the setting of COVID-19, T-cell responses arise earlier than antibodies and persist in the blood for longer.
Patients ordering T-Detect COVID have the opportunity to contribute to ongoing research to further the understanding of T cell-based immunity to COVID-19. This is particularly important as scientists work to define immunity and establish correlates of protection to SARS-CoV-2, the virus that causes COVID-19, resulting from natural infection or vaccination.
About the T cell
T cells are the adaptive immune system's first responders to detect any virus. They quickly multiply and circulate in the blood to attack the virus, often before symptoms appear. Among many other jobs, T cells also recruit B cells to produce antibodies after about a week or two to potentially provide immunity against future infection. T cells contain a treasure trove of information that could provide one consistent and trackable measure of the immune response to COVID-19 from initial exposure through viral clearance.
T cells can 'remember' prior infections and kill pathogens if they reappear. Research shows that antibodies to SARS-CoV-2 decline over time. T cells hold important clues to immunity and correlates of protection and need to be studied to assess how long patients remain resistant to reinfection. Given T cells circulate freely in the blood, they are an easy and thus a desirable target for assessing SARS-CoV-2 exposure and potentially immunity.
About T-Detect
T-Detect is a highly sensitive and specific diagnostic test under development for multiple diseases, translating the natural diagnostic capability of T cells into clinical practice. In 2018, Adaptive and Microsoft partnered to build a map of the immune system called the TCR-Antigen Map. This approach uses immunosequencing, proprietary computational modeling, and machine learning to map T-cell receptor sequences to disease-associated antigens for infectious diseases, autoimmune disorders and cancer. From a simple blood draw, T-Detect will leverage the map to provide an immunostatus for an individual, enabling early disease diagnosis, disease monitoring, and critical insights into immunity. T-Detect COVID is the first clinical test launched from this collaboration and the first commercially available T-cell test designed to detect recent or prior SARS-CoV-2 infections. T-Detect COVID is an in vitro diagnostic that is available for prescription use only. This test has not been cleared or approved by the FDA and is available for use as a CLIA-validated laboratory developed test (LDT). T-Detect COVID is not indicated for use in patients under age 18.
About
Forward Looking Statements
This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations, including forward-looking statements contained in this press release or elsewhere related to T-Detect COVID and its ability to detect recent or past COVID-19 infection, either in its current form or with respect to future mutations of the virus, as well as the potential application of T-Detect to additional disease states.
In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents we file with the
Contact:
Tel: 917-912-7195
Email: media@adaptivebiotech.com
(C) 2021 Electronic News Publishing, source